Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell‐Mediated and Humoral Immunity Against Influenza Virus
Source abstract
Abstract
Abstract Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene‐based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin‐12. Furthermore, co‐administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen‐specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical and Biomolecular Engineering Yonsei University Yonsei‐ro 50 Seoul 03722 Republic of Korea
College of Pharmacy Korea University Sejong‐ro Sejong 30019 Republic of Korea
Department of Microbiology and Infectious Diseases College of Veterinary Medicine Vietnam National University of Agriculture Hanoi 100000 Vietnam
Huvet Bio Inc. 127 Beobwon‐ro Seoul 05836 Republic of Korea
Funding
National Research Foundation of Korea · Ministry of Science, ICT and Future Planning
References (31)
Show source-provided references
1. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
2. 10.1038/nm.340910.1038/nm.3409 ↗
3. 10.1016/j.vaccine.2014.06.04310.1016/j.vaccine.2014.06.043 ↗
4. 10.1016/j.addr.2009.09.00510.1016/j.addr.2009.09.005 ↗
5. 10.1016/j.jim.2003.11.00210.1016/j.jim.2003.11.002 ↗
6. 10.1038/nbt.234410.1038/nbt.2344 ↗
7. 10.1016/j.vaccine.2013.11.06910.1016/j.vaccine.2013.11.069 ↗
8. 10.1038/nri348810.1038/nri3488 ↗
9. 10.1002/adfm.20160065010.1002/adfm.201600650 ↗
10. 10.1016/j.immuni.2016.02.00410.1016/j.immuni.2016.02.004 ↗
11. 10.1021/nn305466z10.1021/nn305466z ↗
12. 10.1002/adhm.20160075010.1002/adhm.201600750 ↗
13. 10.1016/j.jconrel.2017.04.02710.1016/j.jconrel.2017.04.027 ↗
14. 10.1039/c1nr10166h10.1039/c1nr10166h ↗
15. 10.1016/j.vaccine.2009.07.01210.1016/j.vaccine.2009.07.012 ↗
16. 10.1038/srep2450610.1038/srep24506 ↗
17. 10.1016/j.biomaterials.2012.09.06210.1016/j.biomaterials.2012.09.062 ↗
18. 10.1016/j.biomaterials.2010.07.05610.1016/j.biomaterials.2010.07.056 ↗
19. 10.1002/anie.20100507510.1002/anie.201005075 ↗
20. 10.1002/ange.20100507510.1002/ange.201005075 ↗
21. 10.1016/j.biomaterials.2015.03.00610.1016/j.biomaterials.2015.03.006 ↗
22. 10.1016/j.biomaterials.2013.02.00610.1016/j.biomaterials.2013.02.006 ↗
23. 10.1002/smll.20170081810.1002/smll.201700818 ↗
24. 10.1021/nn404055310.1021/nn4040553 ↗
25. 10.1038/ni.312310.1038/ni.3123 ↗
26. 10.1038/ni.203910.1038/ni.2039 ↗
27. 10.3390/ijms1103078910.3390/ijms11030789 ↗
28. 10.1016/j.cell.2007.10.04610.1016/j.cell.2007.10.046 ↗
29. 10.1186/s13567-016-0400-710.1186/s13567-016-0400-7 ↗
30. 10.1002/anie.20130288110.1002/anie.201302881 ↗
31. 10.1002/ange.20130288110.1002/ange.201302881 ↗